

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
February 7, 2019**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Harpoon Therapeutics, Inc.

File No. 333-229040 - CF#36843

Harpoon Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on December 27, 2018, as amended.

Based on representations by Harpoon Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 2.1	through December 30, 2021
Exhibit 10.11	through October 24, 2028
Exhibit 10.12	through October 24, 2028
Exhibit 10.14	through October 24, 2028
Exhibit 10.15	through December 12, 2028
Exhibit 10.16	through December 12, 2028
Exhibit 10.21	through December 12, 2028

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary